The Day by day Biotech Pulse: Bristol-Myers Squibb’s Pores and skin Most cancers Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut
This is a roundup of prime developments within the biotech area over the past 24 hours: Scaling The Peaks (Biotech Shares Hitting 52-week Highs March 24) F-star Therapeutics, Inc. (NASDAQ: FSTX) IDEAYA Biosciences, Inc. (NASDAQ: IDYA) Orphazyme A/S (NASDAQ: ORPH) Ortho Scientific Diagnostics Holdings plc (NASDAQ: OCDX) Down In The Dumps (Biotech Shares Hitting 52-week Lows March 24) Adagene Inc. (NASDAQ: ADAG) Biophytis SA (NASDAQ: BPTS) Live performance Prescribed drugs, Inc. (NASDAQ: CNCE) Join Biopharma Holdings Restricted (NASDAQ: CNTB) (went public Friday) Decibel Therapeutics, Inc. (NASDAQ: DBTX) Dyne Therapeutics, Inc. (NASDAQ: DYN) Epizyme, Inc. (NASDAQ: EPZM) Evaxion Biotech A/S (NASDAQ: EVAX) Finch Therapeutics Group, Inc. (NASDAQ: FNCH) (went public Friday) Forma Therapeutics Holdings, Inc. (NASDAQ: FMTX) Galapagos NV (NASDAQ: GLPG) Galecto, Inc. (NASDAQ: GLTO) Gracell Biotechnologies Inc. (NASDAQ: GRCL) Ibere Prescribed drugs (NYSE: IBER-UN) Inhibikase Therapeutics, Inc. (NASDAQ: IKT) Karyopharm Therapeutics Inc. (NASDAQ: KPTI) MorphoSys AG (NASDAQ: MOR) Metacrine, Inc. (NASDAQ: MTCR) Odonate Therapeutics, Inc. (NASDAQ: ODT) Olema Prescribed drugs, Inc. (NASDAQ: OLMA) Reviva Prescribed drugs Holdings, Inc. (NASDAQ: RVPH) Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Sigilon Therapeutics, Inc. (NASDAQ: SGTX) Talis Biomedical Company (NASDAQ: TLIS) uniQure N.V. (NASDAQ: QURE) Universe Prescribed drugs INC (NASDAQ: UPC) Vallon Prescribed drugs, Inc. (NASDAQ: VLON) Voyager Therapeutics, Inc. (NASDAQ: VYGR) Shares In Focus Neurocrine to Be a part of S&P MidCap 400 Index Commonplace & Poor’s introduced that Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will substitute O-I Glass Inc. (NYSE: OI) within the S&P MidCap 400 efficient March 30. The inventory was up 8.98% premarket at $95.43. Cellect Biotech to Merge With Specialty Pharma Firm Quoin Cellect Biotechnology Ltd. (NASDAQ: APOP) introduced a merger settlement with privately held specialty pharma firm Quoin Prescribed drugs Inc. The settlement offers for Cellect shareholders proudly owning 25% of the mixed firm in comparison with 75% by Quoin shareholders. Completion of the merger is topic to approval of shareholders of each corporations and sure different circumstances. The closing of the transaction is predicted by the top of the second quarter of 2021. Following the completion of the merger, Cellect will probably be renamed Quoin Prescribed drugs and can start buying and selling on NASDAQ beneath the image QNRX. The inventory was up 45.85% premarket at $5.09. Midatech Broadcasts Time period Settlement To Co-Develop MTX110 Midatech Pharma plc (NASDAQ: MTP) mentioned the heads of phrases of the settlement for codeveloping MTX110 has been agreed, and if the deal progresses to definitive agreements, the corporate mentioned it expects to obtain a modest upfront cost on execution, success-based improvement and gross sales milestones and royalties. The corporate additionally launched headline unaudited outcomes, displaying decrease revenues and a wider loss for fiscal yr 2020. The inventory was up 3.41% to $2.12 in premarket buying and selling Thursday. Vertex Broadcasts Australian Regulatory Nod For Triple Combo Cystic Fibrosis Remedy Vertex Prescribed drugs Integrated (NASDAQ: VRTX) mentioned the Australian Therapeutic Items Administration has accepted the usage of Trikafta for folks with cystic fibrosis, ages 12 years and older who’ve at the least one F508del mutation within the cystic fibrosis transmembrane conductance regulator gene, the commonest CF-causing mutation worldwide. Associated Hyperlink: FDA Choices For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Information And Earnings Bristol-Myers Squibb Opdivo-Antibody Combo Remedy Aces Part 2/3 Pores and skin Most cancers Examine Bristol-Myers Squibb (NYSE: BMY) introduced optimistic main outcomes from the Part 2/3 trial evaluating the fixed-dose mixture of relatlimab, an anti-LAG-3 antibody, and Opdivo versus Opdivo alone in sufferers with beforehand untreated metastatic or unresectable melanoma. The corporate mentioned the trial met its main endpoint of progression-free survival. Comply with-up for general survival, a secondary endpoint, is ongoing. Moreover, the fixed-dose mixture was well-tolerated and there have been no new security indicators reported in both the relatlimab and Opdivo mixture arm or the Opdivo arm. G1’s Just lately Accredited Cosela Included In 2 Up to date Most cancers Therapy Tips G1 Therapeutics, Inc. (NASDAQ: GTHX) mentioned its Cosela has been added to 2 up to date Nationwide Complete Most cancers Community Scientific Apply Tips in Oncology: the Therapy Tips for Small Cell Lung Most cancers and the Supportive Care Tips for Hematopoietic Progress Elements. View extra earnings on IBB It just lately received the FDA nod for mitigating the results of chemotherapy in lung most cancers sufferers. The inventory was up 1.76% at $20.80 in premarket buying and selling Thursday. Synlogic Says Hyperoxaluria Therapy Achieves Proof of Mechanism In Part 1 Examine Synlogic, Inc. (NASDAQ: SYBX) introduced that SYNB8802 has achieved proof of mechanism in a dietary hyperoxaluria Part 1 Half A examine during which wholesome volunteers on a excessive oxalate and low calcium weight loss plan had been handled with a number of ascending doses of SYNB8802. Within the examine’s efficacy evaluation, the p.c change from baseline urinary oxalate ranges had been damaging 28.6% in comparison with placebo, on the 3e11 dwell cell dose. This dose was properly tolerated and will probably be utilized in Half B of the examine, the corporate mentioned. The inventory was down 6.96% premarket at $3.61. Radius, Sio-Gene Achieve On Insider Transactions Radius Well being, Inc. (NASDAQ: RDUS) mentioned in a submitting its chief enterprise officer Chhaya Shah exercised choices to purchase shares. Sio Gene Therapies, Inc. (NASDAQ: SIOX) revealed in a submitting its CEO Pawan Cheruvu purchased 100,000 shares within the firm at $2.4814. In after-hours buying and selling, Radius inventory was up 19.49% to $27.50, whereas Sio Gene gained 8.97% to $2.55. Earnings TELA Bio, Inc.’s (NASDAQ: TELA) fourth-quarter income climbed 17% year-over-year to $5.7 million in 2020, and the loss per share narrowed from $1.22 to 54 cents. The inventory climbed 14.29% to $16 in after-hours buying and selling. Choices Evofem Biosciences, Inc. (NASDAQ: EVFM) priced its underwritten public providing of 17.143 million shares of its widespread inventory at a worth to $1.75 per share. The gross proceeds from the providing to Evofem are anticipated to be roughly $30 million. The providing is predicted to shut on or about March 29. All the shares of widespread inventory within the providing are to be bought by Evofem. In after-hours buying and selling, the inventory fell 10.73% to $2.08. On The Radar Adcom Assembly The FDA’s Arthritis Advisory Committee, together with the Drug Security and Threat Administration Advisory Committee will possible announce its suggestion on Pfizer Inc.’s (NYSE: PFE) biologic license utility for tanezumab subcutaneous injection for the proposed indication of reduction of indicators and signs of average to extreme osteoarthritis in grownup sufferers for whom use of different analgesics is ineffective or not acceptable. Tanezumab is being collectively developed by Pfizer and Eli Lilly and Firm (NYSE: LLY). Earnings Vascular Biogenics Ltd. (NASDAQ: VBLT) (earlier than the market open) Genetron Holdings Restricted (NASDAQ: GTH) (earlier than the market open) Synlogic (earlier than the market open) NovaBay Prescribed drugs, Inc. (NYSE: NBY) (after the shut) Neoleukin Therapeutics, Inc. (NASDAQ: NLTX) (after the shut) OpGen, Inc. (NASDAQ: OPGN) (after the shut) Eyenovia, Inc. (NASDAQ: EYEN) (after the shut) HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) (after the shut) CymaBay Therapeutics, Inc. (NASDAQ: CBAY) (after the shut) BIOLASE, Inc. (NASDAQ: BIOL) (after the shut) ADMA Biologics, Inc. (NASDAQ: ADMA) (after the shut) Athersys, Inc. (NASDAQ: ATHX) (after the shut) Processa Prescribed drugs, Inc. (NASDAQ: PCSA) Panbela Therapeutics Inc. (NASDAQ: PBLA) IPOs Dutch biotechnology Lava Therapeutics B.V., which is growing bispecific antibodies engineered to selectively induce gamma-delta T cell-mediated immunity in opposition to tumor cells, priced its 6.7-million share preliminary public providing at $15, the midpoint of the estimated worth vary of $14-$16. The corporate’s shares will start buying and selling on the Nasdaq beneath the ticker image LVTX. Associated Hyperlink: Consideration Biotech Traders: Mark Your Calendar For March PDUFA Dates See extra from BenzingaClick right here for choices trades from BenzingaThe Day by day Biotech Pulse: Dynavax-Clover Begin Part 2/3 Vaccine Examine. BrainStorm Experiences Constructive MS Readout, NeoGenomics Goes ShoppingThe Day by day Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Examine, AlloVir Appoints Gilead Virology Chief As CEO© 2021 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.